Hepatology Research最新文献

{"title":"Comment on “Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis”","authors":"Nobuyuki Toshikuni","doi":"10.1111/hepr.70221","DOIUrl":"10.1111/hepr.70221","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 10","pages":"1568-1569"},"PeriodicalIF":3.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148224704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Steatosis Detected by Abdominal Ultrasonography Is Associated With Worse Prognosis in Underweight Patients","authors":"Makoto Higashino,&nbsp;Hidehiro Murakami,&nbsp;Yusuke Okujima,&nbsp;Toshihide Shima,&nbsp;Hiroaki Miyaoka,&nbsp;Atsushi Nakazawa,&nbsp;Toru Ishikawa,&nbsp;Masanori Kawaguchi,&nbsp;Fusao Ikeda,&nbsp;Norio Horiike,&nbsp;Takeshi Okanoue","doi":"10.1111/hepr.70220","DOIUrl":"10.1111/hepr.70220","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To investigate the prognostic factors of hepatic steatosis detected using abdominal ultrasonography (AUS). After identifying low body mass index (BMI) as a potential risk factor, we explored the association between ultrasound-detected hepatic steatosis (UDHS) and long-term outcomes in underweight patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed 8599 patients who underwent AUS from 2010 to 2015 at six medical centers. Patients with advanced liver disease or viral hepatitis were excluded. In Analysis 1, patients' baseline characteristics were compared between patients with and without UDHS. In Analysis 2, using Cox proportional hazards model, we assessed the risk factors for mortality among patients with UDHS. In Analysis 3, we conducted a propensity score-matched analysis of patients with BMI &lt; 18.5 to evaluate UDHS impact on survival and causes of death. Alcohol consumption data were unavailable; therefore, etiologic classification was not possible.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Altogether, 2370 were diagnosed with UDHS. Male sex, low BMI, and diabetes mellitus were significantly associated with increased mortality among patients with UDHS. Among patients with BMI &lt; 18.5, those with UDHS had significantly higher mortality rate than those without UDHS (43.8% vs. 14.6%, <i>p</i> = 0.0035). Nonhepatic malignancy were the leading cause of death in this group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>UDHS in underweight patients was associated with worse prognosis in this exploratory matched analysis. This finding may suggest a higher-risk subgroup and requires confirmation in larger prospective studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 10","pages":"1509-1515"},"PeriodicalIF":3.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipopolysaccharide Binding Protein and Soluble Mannose Receptor as Biomarkers for Acute Kidney Injury in Cirrhosis","authors":"Hiroyuki Masuda,&nbsp;Tadashi Namisaki,&nbsp;Kosuke Kaji,&nbsp;Norihisa Nishimura,&nbsp;Hiroaki Takaya,&nbsp;Takashi Inoue,&nbsp;Akihiko Shibamoto,&nbsp;Satoshi Iwai,&nbsp;Masayoshi Takami,&nbsp;Yuki Tsuji,&nbsp;Yukihisa Fujinaga,&nbsp;Shinya Sato,&nbsp;Koh Kitagawa,&nbsp;Akira Mitoro,&nbsp;Kiyoshi Asada,&nbsp;Hitoshi Yoshiji","doi":"10.1111/hepr.70217","DOIUrl":"10.1111/hepr.70217","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Predicting renal outcomes in acute kidney injury (AKI) and cirrhosis patients remains challenging. This study aimed to identify AKI-associated biomarkers in cirrhotic patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cross-sectional study included 709 patients with liver cirrhosis, including 91 with AKI and 91 controls. Lipopolysaccharide binding protein (LBP), soluble CD163 (sCD163), and soluble mannose receptor (sMR) plasma levels were analyzed for association with AKI development and prognosis. Risk factors were identified for AKI onset, AKI-associated 90-day mortality, and poor treatment response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Significantly higher LBP, sCD163, and sMR levels were observed in the AKI group versus controls. LBP of ≥ 2550 ng/mL predicted increased risk of AKI in cirrhotic patients. Among patients with AKI, sMR of ≥ 1595 ng/mL predicted 90-day mortality; these patients had significantly reduced cumulative survival versus those with low sMR. Cumulative survival was significantly low among cirrhotic patients with high sMR levels; sMR of ≥ 1460 ng/mL predicted poor treatment response. Significantly more patients with low sMR had Child–Pugh grade A liver cirrhosis and treatment responders versus the high sMR group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>LBP, a bacterial translocation marker, is an early indicator of AKI in cirrhotic patients, and sMR reflects immune activation and is associated with short-term mortality and treatment responsiveness.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 10","pages":"1498-1508"},"PeriodicalIF":3.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide Trends of Noninvasive Tests for Liver Fibrosis in Japan Between 2014 and 2023","authors":"Maito Suoh,&nbsp;Saeed Esmaili,&nbsp;Mohammed Eslam,&nbsp;Jacob George","doi":"10.1111/hepr.70219","DOIUrl":"10.1111/hepr.70219","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 10","pages":"1564-1567"},"PeriodicalIF":3.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline and Longitudinal Liver Stiffness Measurement Predict Outcomes in Primary Biliary Cholangitis: A Multicenter Study","authors":"Yuki Yamashita,&nbsp;Takefumi Kimura,&nbsp;Kaede Fujita,&nbsp;Taiki Okumura,&nbsp;Takanobu Iwadare,&nbsp;Hiroyuki Kobayashi,&nbsp;Shun-ichi Wakabayashi,&nbsp;Tomoo Yamazaki,&nbsp;Satoru Joshita,&nbsp;Takeji Umemura,&nbsp;Masanori Abe,&nbsp;Akinobu Takaki,&nbsp;Kazumichi Abe,&nbsp;Masaaki Takamura,&nbsp;Tadashi Namisaki,&nbsp;Yuki Kugiyama,&nbsp;Atsumasa Komori,&nbsp;Atsushi Tanaka","doi":"10.1111/hepr.70223","DOIUrl":"10.1111/hepr.70223","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE) is a noninvasive tool for assessing severity in primary biliary cholangitis (PBC). While the baseline prognostic value of LSM has been recognized, the clinical significance of longitudinal LSM changes remains underexplored, especially in Asian populations. This study evaluated both baseline and dynamic LSM measurements for predicting adverse outcomes in PBC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter retrospective cohort study analyzed 454 Japanese patients with PBC who underwent VCTE at seven tertiary centers. The primary outcome was a composite of liver-related events, liver transplantation, and all-cause mortality. Kaplan–Meier testing, Cox proportional hazards models, and receiver operating characteristic (ROC) curve analysis were adopted to assess the prognostic performance of baseline LSM and annual LSM changes (ΔLSM/year).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a median follow-up of 4.2 years, 14 patients (3.0%) either died or underwent liver transplantation, and 42 patients (9.3%) experienced liver-related events. Baseline LSM ≥ 8.0 kPa was independently associated with all-cause mortality (hazard ratio 4.79, 95% confidence interval 1.10–20.92). Patients with ΔLSM/year ≥ 2.1 kPa had significantly lower 5-year survival and event-free survival compared with those exhibiting slower disease progression. The area under the ROC curve values of baseline LSM for predicting liver-related events was high at 0.803. Furthermore, LSM ≥ 8.0 kPa stratifies prognosis even in patients who achieved normalization of alkaline phosphatase levels following treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Both baseline and longitudinal increases in LSM predict adverse outcomes in PBC and may signal the need for closer monitoring or early therapeutic intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trail Registration</h3>\u0000 \u0000 <p>Approval number 5313</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 10","pages":"1524-1534"},"PeriodicalIF":3.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Endothelial Cell-Derived Extracellular Vesicles Promote Hepatocellular Carcinoma Progression Through Intercellular Interaction Via miRNA","authors":"Mitsuru Yanagaki,&nbsp;Koichiro Haruki,&nbsp;Munetoshi Akaoka,&nbsp;Hoshiho Kubota,&nbsp;Yu Fujita,&nbsp;Masayuki Shimoda,&nbsp;Kenei Furukawa,&nbsp;Shinji Onda,&nbsp;Yoshihiro Shirai,&nbsp;Tomohiko Taniai,&nbsp;Yuto Yamahata,&nbsp;Toru Ikegami","doi":"10.1111/hepr.70216","DOIUrl":"10.1111/hepr.70216","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The aim of this study was to determine whether the interaction of HCC cells and tumor endothelial cells (TECs) via extracellular vesicle (EV) is involved in the progression of HCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Five sets of matched HCC and adjacent tissues were collected from patients with primary HCC who underwent liver resections. The TECs and normal endothelial cells (NECs) were isolated with magnetic selection of CD31⁺ cells. Condition medium (CM) and EV derived from NECs and TECs were co-cultured with the human HCC cell lines. miRNA sequencing analysis was performed to characterize the miRNA profiles of EVs. Additionally, the relationships between prognosis and miRNA targeted proteins in HCC tissues were analyzed among 121 HCC patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both TECs and NECs exhibited high expression levels of CD31 protein. In tube-forming assays, NECs and TECs formed round tubes characteristic of cultured endothelial cells. Functional assays revealed that TEC-derived CM and EV markedly enhanced migration and invasiveness in HCC cells, whereas NEC-derived CM and EV showed minimal effects. miR-142-3p was significantly upregulated in TECs-derived EVs, which reduced RHOBTB3 expression and promoted HCC migration and invasiveness. miR-20a-5p was significantly downregulated in TECs-derived EVs, which increased ITGB8 expression and promoted HCC migration and invasiveness. Furthermore, low RHOBTB3 and high ITGB8 expression in HCC tissues were significant risk factors for recurrence and survival in HCC patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>TECs-derived EV accelerate HCC progression through intercellular interaction via miRNA, suggesting that TECs can be potential therapeutic target in HCC patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 10","pages":"1484-1497"},"PeriodicalIF":3.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Integrin αvβ6 Autoantibodies as Diagnostic and Monitoring Biomarkers for Pediatric-Onset Primary Sclerosing Cholangitis","authors":"Yukako Maeda,&nbsp;Shuichiro Umetsu,&nbsp;Eitaro Hiejima,&nbsp;Mitsuyoshi Suzuki,&nbsp;Itaru Iwama,&nbsp;Takeshi Kimura,&nbsp;Sonoko Kondo,&nbsp;Ayano Inui,&nbsp;Hiroki Kondou,&nbsp;Tatsuya Okamoto,&nbsp;Takashi Ito,&nbsp;Hiroyuki Shirahase,&nbsp;Kazushi Izawa,&nbsp;Takahiro Yasumi,&nbsp;Takeshi Kuwada,&nbsp;Masahiro Shiokawa,&nbsp;Hiroshi Seno,&nbsp;Junko Takita","doi":"10.1111/hepr.70211","DOIUrl":"10.1111/hepr.70211","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Pediatric primary sclerosing cholangitis (PSC) is a rare progressive cholestatic liver disease that often presents diagnostic challenges owing to overlapping clinical and histological features with autoimmune hepatitis (AIH). We hypothesized that anti-integrin αvβ6 autoantibodies may serve as a noninvasive biomarker to differentiate pediatric PSC from AIH and monitor disease activity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed serum samples from 65 patients with pediatric-onset PSC, 39 with AIH, and 66 controls. Anti-integrin αvβ6 autoantibodies were quantified using enzyme-linked immunosorbent assay. Functional activity of the autoantibodies was assessed using a solid-phase fibronectin-binding inhibition assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Anti-integrin αvβ6 autoantibody levels were significantly higher in pediatric-onset PSC than in AIH and controls. The sensitivity and specificity for distinguishing PSC were 63.9% (95% confidence interval [CI]: 51.4–74.8) and 97.1% (95% CI: 91.9–99.2), respectively. Higher levels were observed in PSC with inflammatory bowel disease than without (<i>p</i> = 0.0069) and in PSC–AIH overlap compared with AIH alone (<i>p</i> = 0.0018). In one case, rising autoantibody levels preceded the clinical transition from AIH to PSC–AIH overlap. Levels declined during remission and after liver transplantation; however, increased again upon recurrence. Functional assays demonstrated that autoantibodies from patients with pediatric-onset PSC inhibited binding of integrin αvβ6 to fibronectin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Anti-integrin αvβ6 autoantibodies may serve as a noninvasive clinically informative biomarker for distinguishing pediatric-onset PSC from AIH and reflecting longitudinal changes in disease activity, including posttransplant recurrence. These findings support their potential clinical utility in the diagnosis and longitudinal assessment of pediatric-onset PSC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 10","pages":"1447-1456"},"PeriodicalIF":3.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic Impact\".","authors":"","doi":"10.1111/hepr.70273","DOIUrl":"https://doi.org/10.1111/hepr.70273","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the Proportion of Hepatitis C Virus Antibody-Positive Patients Who Could be Considered for Direct-Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real-World Cohort Study in Japan.","authors":"Ritsuzo Kozuka, Yoshihito Uchida, Hatsue Fujino, Akira Asai, Tatsuya Ide, Masaru Enomoto, Hiroki Tojima, Hirokazu Takahashi, Jun Inoue, Tadashi Ikegami, Yoshio Tokumoto, Mizuki Endo, Mika Horino, Ryo Sasaki, Tetsuro Shimakami, Koji Sawada, Kazuhito Kawata, Masatsugu Ohara, Kenji Nagata, Takako Inoue, Satoru Kakizaki, Masaaki Korenaga","doi":"10.1111/hepr.70271","DOIUrl":"https://doi.org/10.1111/hepr.70271","url":null,"abstract":"<p><strong>Background and aims: </strong>Although the widespread use of direct-acting antivirals (DAAs) has reduced the proportion of hepatitis C virus (HCV) antibody-positive patients eligible for antiviral treatment, the current proportion requiring referral for DAA therapy in ophthalmology departments, which have both high testing volumes and high HCV antibody-positive rates, remains unclear.</p><p><strong>Methods: </strong>This nationwide multicenter retrospective cohort study included HCV antibody-positive patients identified through testing in ophthalmology departments at 20 institutions in Japan between 2019 and 2023. The proportions of patients requiring referral for DAA therapy were assessed by electronic medical record (EMR) review across all 20 institutions and by a combination of EMR review and HCV antibody titer determination across nine institutions where antibody titers could be measured.</p><p><strong>Results: </strong>A total of 2792 HCV antibody-positive patients were identified across 20 institutions. Based on EMR review, the proportions requiring referral for DAA therapy were 44.4%, 38.7%, 34.2%, 38.9%, and 42.5% in 2019, 2020, 2021, 2022, and 2023, respectively. Among 1255 HCV antibody-positive patients from 9 institutions where HCV antibody titers could be determined, the corresponding proportions assessed by combined EMR review and antibody titer determination were 28.4%, 23.7%, 20.8%, 22.4%, and 25.9%, respectively. Despite a decline in HCV antibody-positive rates over time, the proportion requiring referral remained high.</p><p><strong>Conclusions: </strong>Although the number of HCV antibody-positive patients in ophthalmology departments has decreased, a considerable proportion could still be considered for DAA therapy. Combining HCV antibody titer determination with EMR review improves the efficiency of identifying patients requiring referral.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of the FIB-3 Index in Patients With Hepatic Encephalopathy Receiving Rifaximin: A Multicenter Retrospective Analysis.","authors":"Takeshi Hatanaka, Satoru Kakizaki, Rintaro Kobayashi, Yuki Kanayama, Satoshi Takakusagi, Takashi Kosone, Atsushi Naganuma, Hiroki Tojima, Yuichi Yamazaki, Hitoshi Takagi, Toshio Uraoka","doi":"10.1111/hepr.70269","DOIUrl":"https://doi.org/10.1111/hepr.70269","url":null,"abstract":"<p><strong>Aims: </strong>This study investigated the prognostic performance of the FIB-3 index, composed of aspartate aminotransferase, alanine aminotransferase, and platelet count, in patients with decompensated cirrhosis and overt hepatic encephalopathy receiving rifaximin therapy.</p><p><strong>Methods: </strong>Between March 2017 and March 2024, 235 patients were included in this multicenter retrospective study. The discriminatory performance of the FIB-3 index for predicting 48-month survival was compared with that of the FIB-4 index, aMAP score, MELD 3.0 score, and Child-Pugh classification.</p><p><strong>Results: </strong>The AUROCs for the FIB-3 index, FIB-4 index, aMAP score, MELD 3.0 score, and Child-Pugh classification were 0.63, 0.58, 0.57, 0.71, and 0.70, respectively. Using the FIB-3 index as the reference model, no statistically significant differences in AUROC were observed between the FIB-3 index and the other models (p = 0.05, 0.2, 0.1, and 0.1, respectively). In the NRI analysis, the FIB-3 index demonstrated significantly better discriminatory performance than the FIB-4 index (p < 0.001) but poorer discriminatory performance than Child-Pugh classification (p < 0.001), whereas no significant differences were observed compared with the aMAP or MELD 3.0 scores (p = 0.2 and 0.1, respectively). In the IDI analysis, the FIB-3 index showed significantly better discriminatory performance than the FIB-4 index (p = 0.02) but poorer discriminatory performance than the MELD 3.0 score and Child-Pugh classification (p = 0.004 and p < 0.001, respectively).</p><p><strong>Conclusions: </strong>The FIB-3 index showed better prognostic discrimination than the FIB-4 index and may serve as a simple age-independent fibrosis-related marker that complements established liver function-based prognostic models.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148968122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}